Literature DB >> 27651406

Polycythaemia: an unusual presentation of multiple myeloma.

Elaine J Hutchison1, Josephine A Taverna2, Qi Yu1, Andrew M Yeager2.   

Abstract

In contrast to anaemia, polycythaemia is a distinctly uncommon finding in patients with multiple myeloma. We describe the presence of otherwise unexplained polycythaemia in a 57-year-old Caucasian man who was found to have IgG κ multiple myeloma. After treatment of myeloma, the polycythaemia resolved. We reviewed previous reports of polycythaemia associated with multiple myeloma and discuss potential pathophysiological mechanisms that link these 2 conditions. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27651406      PMCID: PMC5030570          DOI: 10.1136/bcr-2016-216686

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  29 in total

1.  Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure.

Authors:  Hasan Bazari; Eyal C Attar; Douglas M Dahl; Raul N Uppot; Robert B Colvin
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.

Authors:  S S Kenderian; F G Rosado; D B Sykes; J D Hoyer; M Q Lacy
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 3.  Hematological paraneoplastic syndromes.

Authors:  H Staszewski
Journal:  Semin Oncol       Date:  1997-06       Impact factor: 4.929

4.  Multiple myeloma associated with polycythemia; report of four cases.

Authors:  J H LAWRENCE; R L ROSENTHAL
Journal:  Am J Med Sci       Date:  1949-08       Impact factor: 2.378

5.  The TEMPI syndrome--a novel multisystem disease.

Authors:  David B Sykes; Wilfried Schroyens; Casey O'Connell
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

Review 6.  JAK2 mutation-negative secondary erythrocytosis in smoldering plasma cell myeloma: a case study and review of the literature.

Authors:  Sang-Guk Lee; Gayoung Lim; Sun Young Cho; Jin-Tae Suh; Hee Joo Lee; Sun Kyung Baek; Woo-In Lee; Hwi-Joong Yoon; Tae Sung Park
Journal:  Acta Haematol       Date:  2011-07-27       Impact factor: 2.195

7.  Concurrence of multiple myeloma and idiopathic erythrocytosis.

Authors:  H Chang; L Y Shih
Journal:  Acta Clin Belg       Date:  2009 Sep-Oct       Impact factor: 1.264

8.  Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production.

Authors:  Y Beguin; M Yerna; M Loo; M Weber; G Fillet
Journal:  Br J Haematol       Date:  1992-12       Impact factor: 6.998

9.  Polycythemia associated with myeloma.

Authors:  K Maeda; J Abraham
Journal:  Am J Clin Pathol       Date:  1984-10       Impact factor: 2.493

10.  Bortezomib to treat the TEMPI syndrome.

Authors:  Mary Kwok; Neha Korde; Ola Landgren
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

View more
  2 in total

Review 1.  TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.

Authors:  Jian Xu; Wenqi Liu; Fengjuan Fan; Bo Zhang; Fei Zhao; Yu Hu; Chunyan Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

2.  Concurrent Polycythemia of Undetermined Etiology and Smouldering Plasma Cell Myeloma.

Authors:  Roula Katerji; Chad A Hudson
Journal:  Case Rep Pathol       Date:  2018-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.